April 13, 2023
Neil Clark of Destiny Pharma: Our number one target is a deal on XF-73 this year – Vox...
Destiny Pharma CSO discusses breakthrough treatment for C. difficile infection
March 24, 2023
Neil Clark of Destiny Pharma discusses XF-73’s significant Phase 2 data published in a...
March 6, 2023
Neil Clark updates Proactive Investors on progress
February 24, 2023
Neil Clark & Shaun Claydon of Destiny Pharma: Collaboration for NTCD-M3 worth up to...
November 23, 2022
Neil Clark speaks to Labiotech about Antimicrobial Resistance
November 18, 2022
Bill Love speaks to Proactive Investors on addressing the Global Threat of superbugs and...
October 5, 2022
Neil Clark speaks to StockBox Media on NTCD-M3
September 8, 2022
Neil Clark & Shaun Claydon of Destiny Pharma: Significant progress in H1 will conti...
July 19, 2022
Destiny Pharma discusses positive update from FDA on their XF-73 nasal gel